Baricitinib

Baricitinib was developed in the 2000s by researchers at Eli Lilly and Incyte, who were investigating small molecules capable of modulating the immune system. The drug was named through a combination of chemical nomenclature and branding considerations. Researchers, along with clinical collaborators, developed the medication, which was later approved by the FDA in 2018 for the treatment of moderate-to-severe rheumatoid arthritis. Baricitinib is an oral medication commonly used to reduce inflammation and immune overactivity in conditions such as rheumatoid arthritis by inhibiting enzymes called Janus kinases (JAKs), which are essential for immune signaling. It is available by prescription and may be used alone or in combination with other disease-modifying antirheumatic drugs (DMARDs). Baricitinib works by blocking JAK enzymes, which prevents overactive immune responses and reduces inflammation.

BRAND NAMES

Olumiant – used globally for rheumatoid arthritis and some other inflammatory conditions

In some regions, generic baricitinib is also available once patent protections have expired. In certain countries, it has also been used under the same brand for hospitalized COVID-19 patients in combination therapies.

MECHANISM OF ACTION

Baricitinib works by inhibiting Janus kinase (JAK) enzymes, specifically JAK1 and JAK2, which play a key role in immune cell signaling. By blocking these enzymes, it reduces the production of inflammatory proteins, helping to decrease inflammation and immune overactivity in conditions like rheumatoid arthritis.

PHARMACOKINETICS

Absorption

Baricitinib is rapidly absorbed after oral administration, with peak blood levels reached within about 1–2 hours. Its oral bioavailability is high, meaning most of the drug enters the bloodstream efficiently. Food has minimal effect on its absorption, so it can be taken with or without meals.

Distribution

Baricitinib is moderately distributed throughout the body, with a volume of distribution of approximately 76 L. It is about 50% bound to plasma proteins, which allows it to circulate freely and reach target tissues, including joints and immune cells.

Metabolism

Baricitinib undergoes minimal metabolism in the body. The primary metabolic pathway involves CYP3A4 enzymes in the liver, but most of the drug is excreted unchanged, meaning metabolism plays a relatively minor role in its elimination. This reduces the likelihood of significant drug–drug interactions from metabolism alone.

Excretion

Baricitinib is mainly eliminated through the kidneys, with about 75% of the dose excreted unchanged in urine. Its elimination half-life is approximately 12–14 hours, allowing for once-daily dosing in most patients.

PHARMACODYNAMICS

Baricitinib works by blocking JAK1 and JAK2 enzymes, which are involved in immune cell signaling. This reduces the activity of inflammatory cytokines, helping to control inflammation and tissue damage in conditions like rheumatoid arthritis.

ADMINISTRATION

Baricitinib is taken orally as a tablet, usually once daily, with or without food. The dose may be adjusted based on kidney function, age, or other medications. It is prescribed by a healthcare professional, and patients are monitored regularly for side effects and blood test abnormalities during treatment

DOSAGE AND STRENGTH

• Standard dose for rheumatoid arthritis (adults): 2 mg or 4 mg once daily, depending on disease severity and patient factors.

• Tablet strengths available: 2 mg and 4 mg oral tablets

• Adjustments: Dose may be reduced in patients with moderate to severe kidney impairment or increased risk of infections.

FOOD INTERACTIONS

Baricitinib can be taken with or without food, as food has minimal effect on its absorption. There are no major food interactions reported, so patients do not need to adjust meals when taking the medication.

DRUG INTERACTIONS

Baricitinib can interact with several medications, affecting its effectiveness or increasing the risk of side effects:

• Strong CYP3A4 inducers (e.g., rifampin) may slightly reduce baricitinib levels.

• Other immunosuppressants (like biologics or high-dose corticosteroids) can increase the risk of infections.

• Drugs affecting kidney function may alter baricitinib elimination, requiring dose adjustment.

• should be avoided during treatment, as baricitinib can reduce the immune response.

CONTRAINDICATIONS

• Active serious infections (e.g., tuberculosis, sepsis, or severe bacterial, viral, or fungal infections)

• Pregnancy and breastfeeding unless specifically advised by a doctor, due to potential risks to the fetu or infant

SIDE EFFECTS

• Upper respiratory infections (e.g., cold, sinus infection)

• Headache

• Nausea

• Increased blood cholesterol Serious but less common side effects:

• Serious infections (tuberculosis, bacterial or viral infections)

• Changes in blood counts (low white blood cells or platelets)

• Liver enzyme elevations

TOXICITY

Baricitinib toxicity can occur with overdose or prolonged use, leading to serious effects such as low blood cell counts, liver damage, increased risk of infections, and blood clots. There is no specific antidote, so treatment involves stopping the drug and providing supportive care while monitoring and managing complications.